The Latest Breaking News from Pfizer

Britain became the first country to approve a “bivalent” jab on Monday that directly targets Omicron and the original Covid-19 strain - as 29 million people will initially be invited for the vaccine

Roughly 29 million people are eligible for an autumn booster but there are just 13 million doses of the new bivalent Moderna jab available

The comments come after it emerged that current stock would cover only half the population eligible for the booster jab.

Some people will be offered a Moderna jab and others the Pfizer vaccine

Albert Bourla has already received four doses of the Pfizer-BioNTech vaccine

The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms

The autumn booster program for Covid vaccinations will begin shortly. Over 50s, carers, frontline health workers and those at clinical risk will be inited to get a booster jab.

The groundbreaking Moderna jabs, which target both the Omicron variant and the original strain of the killer virus, will be rolled out in a bid to avoid a winter NHS nightmare

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…